|
|
|
Genaissance, Astrazeneca Ink Genomics Agreement
|
Business New Haven
1/21/2002
By: BNH
|
NEW HAVEN - Genaissance Pharmaceuticals Inc. (NASDAQ: GNSC) has entered into an agreement with the UK-based AstraZeneca PLC (NYSE: AZN) in which the companies will apply Genaissance technology to one of AstraZeneca's target discovery programs. AstraZeneca will gain access to specific HAP Markers from Genaissance's HAP Database and also utilize the DecoGen Informatics platform for correlating HAP Markers to disease and/or clinical outcomes. A major international health-care business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services, AstraZeneca is one of the top five pharmaceutical companies in the world, with annual health-care sales of $15.8 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
